Skip to content
DataLookout
Menu

NCT06838273

A Study of BL-B01D1 in Combination With Osimertinib Versus Osimertinib as First-Line Treatment in Patients With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer(PANKU-Lung04)

StatusActive, Not Recruiting
PhasePhase 3
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 7 versions: 7 with changes below. See every version on ClinicalTrials.gov ↗

  1. Notable Eligibility criteria expanded, about 39 words Show 4 more changesShow less
    • Enrollment closed, study ongoing
    • Enrollment target: estimated 720 to confirmed 724
    • Secondary endpoints: details revised at 2 of 6 entries
    • Site details revised
  2. Minor Study title revisedv6
  3. Minor Enrollment target: 696 to 720v5
  4. Minor Interventions: BL-B01D1 and Osimertinib (Drug), Osimertinib (Drug) to BL-B01D1 (Drug), Osimertinib (Drug), Osimertinib (Drug)v4
  5. Notable Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of Mar 2025 to Feb 24, 2025
    • Site details revised
    v3
  6. Minor Interventions: BL-B01D1 (Drug), Osimertinib (Drug) to BL-B01D1 and Osimertinib (Drug), Osimertinib (Drug)v2
  7. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Progression-free survival (PFS)
Timeframe: Up to approximately 36 months

Secondary (6)

Overall survival (OS)
Objective Response Rate (ORR)
Disease Control Rate (DCR)
Duration of Response (DOR)
Treatment Emergent Adverse Event (TEAE)
Show 1 moreShow less
Anti-drug antibody (ADA)

Arms and interventions

BL-B01D1 in Combination with OsimertinibExperimental

Participants receive BL-B01D1 in Combination with Osimertinib for the first cycle (3 weeks). Participants with clinical benefit could receive additional treatment for more cycles. The administration will be terminated because of disease progression or intolerable toxicity occurring or other reasons.

OsimertinibActive comparator

Participants receive Osimertinib for the first cycle (3 weeks). Participants with clinical benefit could receive additional treatment for more cycles. The administration will be terminated because of disease progression or intolerable toxicity occurring or other reasons.

Drugs: BL-B01D1, Osimertinib

Sites

1 site in 1 country

  • Shanghai East HospitalShanghai, Shanghai Municipality, China